RAD50 and ovarian carcinoma: In 2020, PARP inhibitors were used for ovarian cancer patients with mutations in 14 HRR genes including RAD50 [14,15], which provides potential therapeutic targets and options for treating ovarian cancer patients with mutations in HRR mutations.